SCHEMBL10112175

SCHEMBL10112175

Brc1ccc2c(-c3ccncc3)n[nH]c2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.58
DCLK1 O15075 1/20 0.58
PRKD3 O94806 1/20 0.58
MAP4K4 O95819 1/20 0.58
CHEK2 O96017 1/20 0.58
CSF1R P07333 1/20 0.58
FER P16591 1/20 0.58
CDK2 P24941 1/20 0.58
MARK3 P27448 1/20 0.58
FLT4 P35916 1/20 0.58
FLT3 P36888 1/20 0.58
MAPK9 P45984 1/20 0.58
CSNK1D P48730 1/20 0.58
CLK2 P49760 1/20 0.58
CSNK2A1 P68400 1/20 0.58
CSNK1G2 P78368 1/20 0.58
MAP4K2 Q12851 1/20 0.58
STK3 Q13188 1/20 0.58
CAMK2B Q13554 1/20 0.58
CAMK2G Q13555 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2731639 0.88 FLT3 (0.75) DYRK1ADCLK1PRKD3MAP4K4CHEK2
SCHEMBL1362524 0.84 CDK2 (0.75) DYRK1ADCLK1PRKD3MAP4K4CHEK2
SCHEMBL31210155 0.81 CDK2 (0.71) DYRK1ADCLK1PRKD3MAP4K4CHEK2
SCHEMBL4217257 0.81 AXL (0.58) DYRK1ADCLK1PRKD3MAP4K4CHEK2
SCHEMBL29549117 0.81 MAP2K4 (0.61) DYRK1ADCLK1PRKD3MAP4K4CHEK2
SCHEMBL4215112 0.81 MAP2K4 (0.61) DYRK1ADCLK1PRKD3MAP4K4CHEK2
SCHEMBL16025664 0.81 AXL (0.51) DYRK1ADCLK1PRKD3MAP4K4CHEK2
SCHEMBL4219256 0.78 PDPK1 (0.54) DYRK1ADCLK1PRKD3MAP4K4CHEK2
SCHEMBL4220816 0.78 AXL (0.55) DYRK1ADCLK1PRKD3MAP4K4CHEK2
SCHEMBL2945771 0.77 NTRK1 (0.49) DYRK1ADCLK1PRKD3MAP4K4CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180305331-A1 PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS SELVITA S.A. (PL) 2018-10-25 US disclosed
EP-3365337-A1 PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS Selvita S.A. (PL) 2018-08-29 EP disclosed
CN-108349956-A PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS 赛尔维他股份公司 2018-07-31 CN disclosed
WO-2017068064-A1 PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS SELVITA S.A. (PL) 2017-04-27 WO disclosed
US-8541572-B2 Compounds for the treatment of inflammatory disorders MERCK SHARP & DOHME CORP. (US) 2013-09-24 US disclosed
US-8541572-B2 Compounds for the treatment of inflammatory disorders MERCK SHARP & DOHME CORP. (US) 2013-09-24 US disclosed
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME CORP. 2012-01-12 US disclosed
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME CORP. 2012-01-12 US disclosed
WO-2010054279-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS SCHERING CORPORATION (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, ADAMTS1, ADAMTS7 DYRK1A 4205/4885DCLK1 2833/4885PRKD3 4737/4885
US-20180305331-A1 PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS PDXK, PLK2, MAP4K2 DYRK1A 507/4885DCLK1 341/4885PRKD3 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.